Monoclonal Antibodies (MAs) Global Market Report 2026

Monoclonal antibodies (MABs) are proteins created in a laboratory designed to enhance your immune system. Treatments involving monoclonal antibodies are typically given as IV solutions, often at an infusion center. Antibodies are part of your immune system. To destroy harmful substances, they target antigens (foreign substances) and attach to them.

The main types of sources of monoclonal antibodies (mAbs) include murine, chimeric, humanized, and human. A murine antibody consists of two types of chains, one derived from a mouse and the other from a human. The pre-stem -o- in the INN of a murine antibody is used to denote it. It finds applications in anti-cancer, immunological, anti-infective monoclonal antibodies (mAbs), as well as in neuropharmacological, cardiovascular, cerebrovascular, and other therapeutic areas, and is utilized across various settings such as hospitals, private clinics, and research institutes.

Tariffs have impacted the monoclonal antibodies market by raising the cost of biologic raw materials, bioreactor components, and cold chain logistics required for large scale antibody production. These impacts are most visible in oncology and immunological applications, where manufacturing complexity and supply continuity are critical. Regions such as North America and Europe have experienced higher input costs due to dependence on global biologics supply chains. Rising tariff related expenses have influenced production economics, pricing strategies, and capacity planning for monoclonal antibody therapies. However, tariffs have also promoted local biologics manufacturing, expanded regional production capacity, and strengthened biopharmaceutical ecosystems over the long term.

The monoclonal antibodies (mas) market research report is one of a series of new reports from The Business Research Company that provides monoclonal antibodies (mas) market statistics, including monoclonal antibodies (mas) industry global market size, regional shares, competitors with a monoclonal antibodies (mas) market share, detailed monoclonal antibodies (mas) market segments, market trends and opportunities, and any further data you may need to thrive in the monoclonal antibodies (mas) industry. This monoclonal antibodies (mas) market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The monoclonal antibodies (mas) market size has grown rapidly in recent years. It will grow from $256.03 billion in 2025 to $288.78 billion in 2026 at a compound annual growth rate (CAGR) of 12.8%. The growth in the historic period can be attributed to advances in antibody engineering, rising cancer and autoimmune disease burden, expansion of biologics approvals, improved infusion center infrastructure, increased healthcare spending.

The monoclonal antibodies (mas) market size is expected to see rapid growth in the next few years. It will grow to $464.39 billion in 2030 at a compound annual growth rate (CAGR) of 12.6%. The growth in the forecast period can be attributed to growth in targeted biologics pipelines, increasing use in chronic diseases, expansion of biosimilars, rising immunotherapy adoption, growth of specialty clinics. Major trends in the forecast period include rising demand for biologic-based therapies, increasing use of monoclonal antibodies in oncology, expansion of infusion-based treatment settings, growing adoption of humanized and fully human mabs, increased focus on long-term immunotherapy treatment.

The growing availability of cost-effective biosimilar monoclonal antibodies is anticipated to stimulate the expansion of the monoclonal antibody market. Biosimilars are drugs designed to closely resemble an already approved biological medication. Their increasing use is driven by rising patient demand for affordable biologic treatments, the expiration of patents for major branded monoclonal antibodies, and regulatory frameworks that support the development and commercialization of biosimilars. The adoption of cost-effective biosimilar monoclonal antibodies enhances the monoclonal antibody market by improving treatment accessibility, lowering healthcare costs, and promoting competitive innovation among pharmaceutical companies. For example, in February 2025, the World Health Organization, a Switzerland-based United Nations agency dedicated to global public health, reported that biosimilars are approximately 60% less expensive than original biologic drugs, offering significant cost savings that can broaden access to essential biologic therapies. As a result, the increasing use of cost-effective biosimilar monoclonal antibodies is driving the growth of the monoclonal antibody market.

The growing prevalence of chronic diseases is expected to drive the expansion of the monoclonal antibodies (mAbs) market in the coming years. Chronic diseases are long-term conditions that generally cannot be cured but can be managed through proper medical care and lifestyle modifications. The increase in chronic diseases is attributed to lifestyle changes linked to economic development and urbanization, which result in poor diet, sedentary behavior, higher obesity rates, and associated metabolic risks. Monoclonal antibodies (mAbs) are used in the management of various chronic diseases, especially those involving dysregulated immune responses, excessive inflammation, and specific molecular targets. For example, in July 2023, the Health Foundation, a UK-based independent health policy research and analysis organization, reported that the number of people living with major illnesses in England is expected to rise by 37 percent by 2040, which is nine times higher than the growth rate of the working-age population aged 20 to 69 years at 4 percent. Consequently, the continued rise in chronic disease incidence will continue to fuel the growth of the monoclonal antibodies (mAbs) market.

Major companies operating in the monoclonal antibodies market are adopting innovative technologies such as RenMice to strengthen their position in the market. RenMice provides significant support in the development of various antibody-based therapies, including fully human monoclonal antibodies, bispecific antibodies, bispecific antibody-drug conjugates (BsADCs), nanobodies, fully human T-cell receptors (TCRs), and TCR-mimic antibodies. For example, in September 2023, Biocytogen Pharmaceuticals, a China-based global biotech company focused on advancing drug research and development through innovative technologies, introduced the RenMice series. This series includes a range of independently developed fully human antibody mice and TCR mice, all protected by proprietary intellectual property.

Major companies operating in the monoclonal antibodies (mas) market are Johnson & Johnson, Merck & Co. Inc., AbbVie Inc., Amgen Inc., Novartis International AG, Pfizer Inc., Thermo Fisher Scientific Inc., Eli Lilly and Company, Bristol-Myers Squibb Company, F. Hoffmann-La Roche Ltd., Sanofi S.A., Abbott Laboratories, Daiichi Sankyo Company Ltd., Seattle Genetics Inc., Shanghai Junshi Biosciences Co. Ltd., GenScript Biotech Corporation, Sigma-Aldrich Co. LLC, AbGenomics Inc., ADC Therapeutics SA, Agensys Inc., Alexion Pharmaceuticals Inc., ALMAC Group Ltd., Ambrx Biopharma Inc., Astellas Pharma Inc., Celgene Corporation, Celldex Therapeutics Inc., Baxter International Inc., Fresenius SE & Co. KGaA, Hikma Pharmaceuticals plc, Jiangsu Hengrui Medicine Co. Ltd., Piramal Enterprises Ltd., CD BioSciences Inc., Creative Biolabs Inc., Advanced ChemTech Inc., Tonbo Biosciences Inc., GlaxoSmithKline plc

North America was the largest region in the monoclonal antibodies (MAbS) market in 2025. The regions covered in the monoclonal antibodies (mas) market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

The countries covered in the monoclonal antibodies (mas) market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The monoclonal antibodies (MABS) market consists of sales of rituximab, cetuximab, and trastuzumab. Values in this market are factory gate values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Monoclonal Antibodies (MAs) Market Global Report 2026 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses monoclonal antibodies (mas) market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 16 geographies.
• Assess the impact of key macro factors such as geopolitical conflicts, trade policies and tariffs, inflation and interest rate fluctuations, and evolving regulatory landscapes.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on end user analysis.
• Benchmark performance against key competitors based on market share, innovation, and brand strength.
• Evaluate the total addressable market (TAM) and market attractiveness scoring to measure market potential.
• Suitable for supporting your internal and external presentations with reliable high-quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for monoclonal antibodies (mas) ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward, including technological disruption, regulatory shifts, and changing consumer preferences? The monoclonal antibodies (mas) market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, total addressable market (TAM), market attractiveness score (MAS), competitive landscape, market shares, company scoring matrix, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market. This section also examines key products and services offered in the market, evaluates brand-level differentiation, compares product features, and highlights major innovation and product development trends.
• The supply chain analysis section provides an overview of the entire value chain, including key raw materials, resources, and supplier analysis. It also provides a list competitor at each level of the supply chain.
• The updated trends and strategies section analyses the shape of the market as it evolves and highlights emerging technology trends such as digital transformation, automation, sustainability initiatives, and AI-driven innovation. It suggests how companies can leverage these advancements to strengthen their market position and achieve competitive differentiation.
• The regulatory and investment landscape section provides an overview of the key regulatory frameworks, regularity bodies, associations, and government policies influencing the market. It also examines major investment flows, incentives, and funding trends shaping industry growth and innovation.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include the technological advancements such as AI and automation, Russia-Ukraine war, trade tariffs (government-imposed import/export duties), elevated inflation and interest rates.
• The total addressable market (TAM) analysis section defines and estimates the market potential compares it with the current market size, and provides strategic insights and growth opportunities based on this evaluation.
• The market attractiveness scoring section evaluates the market based on a quantitative scoring framework that considers growth potential, competitive dynamics, strategic fit, and risk profile. It also provides interpretive insights and strategic implications for decision-makers.
• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth.
• Expanded geographical coverage includes Taiwan and Southeast Asia, reflecting recent supply chain realignments and manufacturing shifts in the region. This section analyzes how these markets are becoming increasingly important hubs in the global value chain.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The company scoring matrix section evaluates and ranks leading companies based on a multi-parameter framework that includes market share or revenues, product innovation, and brand recognition.

Scope

• Markets Covered:1) By Source: Murine; Chimeric; Humanized; Human
• 2) By Application: Anti-Cancer; Immunological; Anti-Infective Monoclonal Antibodies (MAs); Neuropharmacological; Cardiovascular And Cerebrovascular; Other Applications
• 3) By End Users: Hospitals; Private Clinics; Research Institute
• Subsegments:
• 1) By Murine: Fully Murine MAbs; Murine-Derived MAbs
• 2) By Chimeric: Chimeric MAbs With Murine Variable Regions; Chimeric MAbs With Human Constant Regions
• 3) By Humanized: Humanized MAbs With Minor Murine Components; Fully Humanized MAbs
• 4) By Human: Fully Human MAbs; Engineered Human MAbs
• Companies Mentioned: Johnson & Johnson; Merck & Co. Inc.; AbbVie Inc.; Amgen Inc.; Novartis International AG; Pfizer Inc.; Thermo Fisher Scientific Inc.; Eli Lilly and Company; Bristol-Myers Squibb Company; F. Hoffmann-La Roche Ltd.; Sanofi S.A.; Abbott Laboratories; Daiichi Sankyo Company Ltd.; Seattle Genetics Inc.; Shanghai Junshi Biosciences Co. Ltd.; GenScript Biotech Corporation; Sigma-Aldrich Co. LLC; AbGenomics Inc.; ADC Therapeutics SA; Agensys Inc.; Alexion Pharmaceuticals Inc.; ALMAC Group Ltd.; Ambrx Biopharma Inc.; Astellas Pharma Inc.; Celgene Corporation; Celldex Therapeutics Inc.; Baxter International Inc.; Fresenius SE & Co. KGaA; Hikma Pharmaceuticals plc; Jiangsu Hengrui Medicine Co. Ltd.; Piramal Enterprises Ltd.; CD BioSciences Inc.; Creative Biolabs Inc.; Advanced ChemTech Inc.; Tonbo Biosciences Inc.; GlaxoSmithKline plc
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Taiwan; Russia; South Korea; UK; USA; Canada; Italy; Spain.
• Regions: Asia-Pacific; South East Asia; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time Series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data Segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: Word, PDF or Interactive Report
• + Excel Dashboard
• Added Benefits
• Bi-Annual Data Update
• Customisation
• Expert Consultant Support

Added Benefits available all on all list-price licence purchases, to be claimed at time of purchase. Customisations within report scope and limited to 20% of content and consultant support time limited to 8 hours.